Cannabis for Epilepsy: Where are We? Editor-In-Chief Dr. Joseph Sirven interviews Orrin Devinsky MD and Daniel Friedman MD about the current state of the use of medical marijuana for epilepsy. Drs. Devinsky and Friedman recently released an article entitled "Cannabinoids in the Treatment of Epilepsy," which was published in the September 10 issue of The New England Journal of Medicine.

Spritam—The first 3D printed drug Editor-In-Chief Dr. Joseph Sirven interviews Aprecia CEO Don Wetherhold about Spritam, the first 3D printed drug. In early August, Aprecia announced that the Food and Drug Administration (FDA) has approved SPRITAM® (levetiracetam) tablets as adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in people with epilepsy. Spritam uses ZipDose® Technology platform, which produces a porous formulation through 3D printing; this allows the formulation to quickly disintegrate with a sip of liquid. Spritam will be available as 250mg, 500mg, 750mg, and 1000mg strengths in 60-count cartons (6x10) in a spearmint flavor. It is expected to be available for prescription in the first quarter of 2016.

Seizure Smart School District Editor-In-Chief Dr. Joseph Sirven interviews Cindy Hiltz, Anoka-Hennepin District 11 Health Services Coordinator, and Katherine Nickels, MD about the Seizure Smart School District in Minnesota.

Hallway Conversations on Seizure Emergencies Editor-In-Chief Dr. Joseph Sirven interviews provides an overview of the latest emerging  options regarding seizures and EEG in the critically ill patient.  This topic was explored at the American Epilepsy Society Course in December 2014. This content is created through a partnership between the Epilepsy Foundation and American Epilepsy Society.

First Seizure Guidelines Editor-In-Chief Dr. Joseph Sirven interviews Dr. Jacqueline French, chief science officer of the Epilepsy Foundation, about newly released guidelines for the treatment of first seizures. This content is created through a partnership between the Epilepsy Foundation and American Epilepsy Society.